Pharmaceuticals, Biotechnology and Life Sciences
Novartis has ended third quarter 2019 with reported net income of $2.0 billion, which as an 8% increase, driven by higher operating income and higher income from associated companies, saying in the press release Tuesday that its EPS was USD 0.90 (+11%, +14% cc), growing faster than net income driven by lower weighted average number of shares outstanding.
Novartis will work with Microsogt to establish AI innovation lab to empower its associates to use AI across the business, on Novartis Campus (Switzerland), at Novartis Global Service Center in Dublin, and at Microsoft Research Lab (UK) – starting with tackling personalized therapies for macular degeneration; cell & gene therapy; and drug design.
Novartis has received FDA approval for Beovu, the only anti-VEGF in wet AMD recommended to maintain eligible patients on up to three-month dosing intervals immediately after the loading phase with no compromise in efficacy, for AMD patients, which are in risk from causes blindness and loss of independence.
Annie Martin, Global Head of Presicion Medicine, has discussed the future of targeted therapy and genomic profiling, describing how to…
Novartis’ company Avexis said that it’s Phase 1/2 Srong study for intrathecal (IT) administration of AVXS-101, showed that patients aged 2 to 5, with spinal muscular atrophy (SMA) Type 2 achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold, at a mean duration of follow-up time of 9.3 months.
Novartis will present results from its trial designated Mnaleesa-3, which showed that ribociclib branded as Kisqali has achieved statistically significant improvement in overall survival (OS), which is – according to Novartis – the only CDK4/6 inhibitor to demonstrate positive overall survival in two pivotal Phase III trials — consistently demonstrating approximately 30% reduction in the risk of death.
Technavio’s market research reports examine the competitive landscape and provide detailed insights into the market scenario over the next five years.
The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to capmatinib (INC280) as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), said John Tsai, MD, Head of Global Drug Development and Chief Medical Officer, Novartis.
Novartis said Tuesday that the USFDA marked its investigational sickle cell drug crizanlizumab for Priority Review, which could be the first monoclonal antibody targeting the P-selectin mediated multi-cellular adhesion in sickle cell disease.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone payments.